5 results
In the present study the effects of the colonic administration of butyrate on portal, hepatic, mesenteric venous and arterial SCFA concentrations will be studied in patients undergoing major upper abdominal surgery. The aim is to clarify the…
The primary objective of this study is to evaluate the proportion of patients achieving FXI inhibition * 80% at trough (Day 91) after monthly dosing at 3 dose levels of MAA868.
Primary Objective:* To evaluate ORR of avelumab in combination with talazoparib, in patients with locally advanced or metastatic solid tumors harboring BRCA1, BRCA2 or ATM defect.Secondary Objective:* To assess the overall safety and tolerability of…
To prove that the RECAP test has the potential of selecting patients who are sensitive to treatment with the PARP inhibitor talazoparib as measured by the PFS rate at 4 months.
PrimaryTo evaluate the efficacy of single agent talazoparib in DNA damage repair (DDR) + metastatic CRPC, as measured by best objective responserate (ORR).Secondary:To evaluate efficacy with respect to the following parameters:• Time to objective…